FDA fast track designation applies to ALK+ NSCLC progressing after ≥2 ALK TKIs, reflecting limited post-lorlatinib ...
Drugs that block enzymes called tyrosine kinases are among the most effective targeted therapies for cancer. However, they ...
AUSTIN, Texas , Oct. 24, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...
A phase Ib/IIa study of DX1002, a novel drug in patients with pretreated advanced hepatocellular carcinoma: Efficacy and safety analysis. Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 ...
The primary cause of lung cancer is smoking. However, the incidence of lung cancer among never-smokers has been steadily increasing, especially among women. While approximately 80% of never-smoking ...
(Left) Distribution of gender among never-smoking lung cancer patients analyzed in this study with predominance of females. (Middle) Screening results for genetic mutations in never-smoking lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results